CRL vs MDLN: fair value comparison
Charles River Laboratories International, Inc. and Medline Inc. · Updated 2026-10-19
MDLN's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, CRL currently ranks higher by quality score.
| CRL | MDLN | |
|---|---|---|
| Verdict | Overvalued | Awaiting full valuation |
| Last price | $301.79 | $35.96 |
| 12-month range | $149.93–$310.77 | $31.64–$49.99 |
| Rank by discount to fair value | #108 of 108 Healthcare | — |
| Rank by quality score | #209 of 301 Healthcare | #211 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Declining | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: CRL fair value analysis · MDLN fair value analysis